Florida International University
Edit Your Profile
FIU Discovery
Toggle navigation
Browse
Home
People
Organizations
Scholarly & Creative Works
Research Facilities
Support
Edit Your Profile
RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
Conference
Gilbert, Mark R, Dignam, James, Won, Minhee
et al
. (2013). RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). .
JOURNAL OF CLINICAL ONCOLOGY,
31(15),
Share this citation
Twitter
Email
Gilbert, Mark R, Dignam, James, Won, Minhee
et al
. (2013). RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). .
JOURNAL OF CLINICAL ONCOLOGY,
31(15),
Copy Citation
Share
International Collaboration
Overview
Research
Location
Additional Document Info
View All
Overview
cited authors
Gilbert, Mark R; Dignam, James; Won, Minhee; Blumenthal, Deborah T; Vogelbaum, Michael A; Aldape, Kenneth D; Colman, Howard; Chakravarti, Arnab; Jeraj, Robert; Armstrong, Terri S; Wefel, Jeffrey Scott; Brown, Paul D; Jaeckle, Kurt A; Schiff, David; Atkins, James Norman; Brachman, David; Werner-Wasik, Maria; Komaki, Ritsuko; Sulman, Erik P; Mehta, Minesh P
sustainable development goals
SDG 03: Good Health and Well-being
authors
Mehta, Minesh
date/time interval
May 31, 2013 -
publication date
May 20, 2013
published in
JOURNAL OF CLINICAL ONCOLOGY
Journal
Research
keywords
Life Sciences & Biomedicine
Oncology
Science & Technology
Location
Location
IL, Chicago
Additional Document Info
Conference
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
publisher
LIPPINCOTT WILLIAMS & WILKINS
volume
31
issue
15